Glucagon-like peptide-1 gene therapy - Sanofi Genzyme

Drug Profile

Glucagon-like peptide-1 gene therapy - Sanofi Genzyme

Alternative Names: Type 2 diabetes gene therapy

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Dec 2016 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 04 May 2006 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 26 Jun 2003 Data presented at the 63rd Scientific Sessions of the American Diabetes Association (ADA-2003)have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top